GSE230634 PARP inhibition 0 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE230634_PARP inhibition_0_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE230634_PARP inhibition_0_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE230634_PARP inhibition_0_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE230634_PARP inhibition_0_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 1599

Gene

long intergenic non-protein coding RNA 2677

Gene

long intergenic non-protein coding RNA 607

Gene

MYLK antisense RNA 1

Gene

MIR130A host gene

Gene

long intergenic non-protein coding RNA 2882

Gene

ARHGEF17 antisense RNA 1

Gene

long intergenic non-protein coding RNA 488

Gene

long intergenic non-protein coding RNA 1535

Gene

CA15 pseudogene 1

  • Gene

    long intergenic non-protein coding RNA 1599


  • Gene

    long intergenic non-protein coding RNA 2677


  • Gene

    long intergenic non-protein coding RNA 607


  • Gene

    MYLK antisense RNA 1



  • Gene

    long intergenic non-protein coding RNA 2882


  • Gene

    ARHGEF17 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 488


  • Gene

    long intergenic non-protein coding RNA 1535


  • Gene

    CA15 pseudogene 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.